Intranasal Drug Delivery Device Sales

Intranasal Drug Delivery Device Sales Market Outlook

The global intranasal drug delivery device market is anticipated to reach approximately USD 5.2 billion by 2035, with a compound annual growth rate (CAGR) of around 7.2% during the forecast period from 2025 to 2035. This growth is significantly driven by the increasing prevalence of chronic diseases, rising demand for non-invasive drug delivery systems, and advancements in technology that enhance the efficacy and reliability of intranasal devices. The healthcare industry is progressively shifting towards patient-centered care, which emphasizes the need for drug delivery systems that are easy to use and offer rapid therapeutic effects. Additionally, with the ongoing COVID-19 pandemic, there has been an acceleration in research and development initiatives focusing on intranasal vaccines and other therapeutics, further propelling market growth.

Growth Factor of the Market

Several factors contribute to the robust growth of the intranasal drug delivery device market. Firstly, the increasing awareness regarding the advantages of intranasal administration over traditional routes, such as oral and injectable methods, has driven demand significantly. Intranasal delivery offers rapid absorption of therapeutic agents due to the rich vascularization of the nasal mucosa, leading to faster onset of action, which is particularly advantageous in emergency situations. Furthermore, the growing prevalence of respiratory disorders, allergies, and neurological conditions has prompted the adoption of intranasal drug delivery devices for effective treatment options. Regulatory approvals for innovative products have also played a crucial role in enhancing market growth, enabling manufacturers to introduce novel solutions that cater to the evolving needs of healthcare providers and patients alike. Lastly, the rise in telehealth services has allowed patients to access intranasal treatments more conveniently, thereby increasing their usage and market penetration.

Key Highlights of the Market

• The increasing prevalence of chronic diseases is driving the demand for effective drug delivery systems.
• Technological advancements in device designs enhance the drug delivery experience and patient adherence.
• Regulatory approvals for innovative intranasal drug delivery devices are on the rise, fostering market growth.
• The rise in telehealth services promotes easier access to intranasal treatments.
• Growing consumer awareness regarding non-invasive treatment options is boosting demand in the market.

By Product Type

Sprays :

Intranasal sprays represent a significant segment of the market, primarily due to their ease of use and rapid action. These devices allow for the direct delivery of medications into the nasal cavity, facilitating swift absorption into systemic circulation. They are extensively used for delivering a wide range of medications, including corticosteroids for allergic rhinitis and emergency medications like naloxone for opioid overdose. The convenience of intranasal sprays, combined with effective dosing mechanisms, has led to their growing adoption among patients and healthcare providers. Furthermore, the continuous innovation in spray formulations has resulted in improved therapeutic effects and minimized side effects, making this segment a key driver of market growth.

Drops :

Intranasal drops are another important type of delivery device used primarily for local delivery of medications in treating conditions such as nasal congestion or postnasal drip. Although they are less popular than sprays due to the potential for less accurate dosing and usability concerns, they still possess a niche market. Often deployed in pediatric settings, intranasal drops are beneficial for younger patients who may find sprays difficult to use. The simplicity of the drop format, combined with its ability to provide localized treatment, underpins its continued relevance in the intranasal drug delivery market.

Powders :

Intranasal powders have gained traction as a delivery method for certain medications, particularly those requiring stable formulations. This format allows for the preservation of drug integrity while also providing an effective delivery mechanism that can facilitate quick absorption through the nasal mucosa. The development of advanced powder formulations that are easy to administer is helping to expand this segment's presence. Intranasal powders are particularly beneficial for administering vaccines and can be advantageous in emergency settings, providing rapid action without the need for liquid formulations, thus enhancing the market's growth potential.

Gels :

Intranasal gels offer unique advantages in drug delivery, primarily due to their ability to provide a sustained release of medication over an extended period. This property makes gels particularly useful for managing chronic conditions that require prolonged therapeutic effects. The stability of gel formulations, coupled with their capacity for targeted delivery, enhances patient compliance and satisfaction. As research continues to refine gel formulations for various therapeutic areas, their usage in intranasal drug delivery is expected to grow, contributing positively to the overall market landscape.

Others :

This segment encompasses various other intranasal drug delivery systems that do not fall under the categories mentioned above. Innovations in this space include devices that utilize newer technologies like microneedles and breath-activated systems. These alternatives are being developed to improve user experience, enhance drug absorption, and increase the variety of medications that can be effectively delivered intranasally. As the market evolves, the "Others" segment is likely to showcase emerging trends and innovations that could reshape the competitive landscape of intranasal drug delivery devices.

By Application

Allergy :

Intranasal drug delivery devices are increasingly applied in managing allergic conditions such as allergic rhinitis. These devices allow for the targeted delivery of antihistamines and corticosteroids to the nasal mucosa, reducing the onset of allergic symptoms rapidly. By providing a localized effect, intranasal treatments minimize systemic exposure, which is particularly beneficial for patients who are sensitive to oral medications. The growing incidence of allergies globally emphasizes the necessity for effective treatment methods, thereby driving the adoption of intranasal devices in allergy management.

Pain Management :

The application of intranasal drug delivery in pain management is emerging as a vital approach, particularly for acute and chronic pain conditions. Medications such as fentanyl can be delivered intranasally, providing rapid analgesic effects without the need for injections. This non-invasive method is especially beneficial for patients who may have difficulty swallowing pills or require immediate relief from pain. The growing emphasis on pain management strategies in the healthcare sector is contributing to the increasing acceptance and utilization of intranasal devices in this application.

Vaccination :

Intranasal vaccination represents a transformative approach in immunization strategies, allowing for non-invasive delivery of vaccines. This method is particularly vital in expanding vaccination coverage, especially in populations hesitant about needles. The COVID-19 pandemic has accelerated interest in intranasal vaccines, leading to the development of various formulations aimed at combating respiratory viruses. As research progresses and regulatory bodies approve more intranasal vaccines, the market is expected to see substantial growth driven by the need for effective and accessible vaccination methods.

Hormonal Disorders :

Intranasal drug delivery devices are also being utilized in managing hormonal disorders, such as diabetes and growth hormone deficiencies. This delivery method allows for the rapid systemic absorption of hormones like desmopressin or insulin, providing effective management for conditions that require quick hormonal adjustments. The convenience of intranasal administration proves beneficial, especially for patients who might struggle with traditional injection methods. The evolving landscape of hormonal treatments coupled with advancements in intranasal delivery technologies is poised to enhance the market's potential in this application area.

Others :

The "Others" category in this segment includes additional applications of intranasal drug delivery devices that cater to specific patient needs and conditions. This may encompass therapies for neurological disorders, such as migraine treatments or conditions involving the central nervous system, where rapid drug action is crucial. As more research emerges highlighting the efficacy of various intranasal formulations for diverse applications, this segment is expected to grow, reflecting the versatility and adaptability of intranasal drug delivery systems in catering to a wide range of healthcare needs.

By Distribution Channel

Hospitals :

Hospitals represent a critical distribution channel for intranasal drug delivery devices, as they are primary care settings where acute and chronic conditions are treated. In hospitals, healthcare professionals can administer intranasal medications swiftly, especially in emergency departments where rapid response is essential. Furthermore, hospitals are increasingly adopting advanced therapeutic protocols that incorporate intranasal devices due to their efficiency and patient-centric benefits. As hospitals continue to expand their treatment options, the demand for intranasal devices is expected to rise significantly in this channel.

Retail Pharmacies :

Retail pharmacies serve as a significant point of access for patients seeking over-the-counter intranasal medications. This distribution channel allows patients to obtain necessary treatments conveniently, promoting adherence to prescribed therapies. With the increasing prevalence of allergies and respiratory disorders, retail pharmacies are expanding their inventory of intranasal devices, making them easily accessible to consumers. The growing trend towards self-medication further boosts this segment, as patients are increasingly willing to explore non-invasive options for managing their conditions.

Online Pharmacies :

The rise of online pharmacies has transformed the way consumers access pharmaceutical products, including intranasal drug delivery devices. This distribution channel provides the added convenience of home delivery, allowing patients to receive their treatments discreetly and without the need to visit a physical store. Online platforms often provide a wider range of product options and competitive pricing, enhancing consumer choice. As e-commerce continues to grow, the online pharmacy segment is expected to capture a larger share of the intranasal drug delivery device market.

Drug Stores :

Drug stores play a crucial role in the distribution of intranasal drug delivery devices by providing patients with a dedicated space to access various healthcare products. These stores often offer a specialized selection of intranasal medications that cater to specific health needs, such as allergies or pain management. With trained pharmacy staff available to assist customers, drug stores can provide valuable advice on the usage and effectiveness of intranasal devices. The increasing emphasis on patient engagement and education within drug stores is likely to facilitate further growth of this distribution channel in the market.

Others :

This segment encompasses various alternative distribution channels that contribute to the availability of intranasal drug delivery devices. These may include specialized clinics, healthcare provider offices, and direct-to-consumer channels that focus on specific patient demographics. As healthcare becomes more personalized, these channels are adapting to meet the evolving needs of patients. The flexibility and accessibility offered by diverse distribution methods enhance the overall market presence of intranasal drug delivery devices, making them available to a broader audience.

By Ingredient Type

Corticosteroids :

Corticosteroids are a prominent ingredient type used in intranasal drug delivery devices, primarily for managing allergic rhinitis and nasal inflammation. These agents work by reducing inflammation and providing relief from symptoms such as nasal congestion, runny nose, and sneezing. The effectiveness of intranasal corticosteroids has solidified their position as a first-line treatment option in many cases, leading to a sustained demand in the market. As more patients shift towards non-invasive treatment options, the utilization of corticosteroids in intranasal formulations is expected to grow considerably.

Antihistamines :

Antihistamines comprise another critical ingredient type in intranasal drug delivery devices, specifically formulated to combat allergic reactions. These medications work by blocking histamine receptors, alleviating symptoms such as itching, sneezing, and nasal congestion. The ease of administration offered by intranasal antihistamines enhances patient compliance, making them a popular choice among healthcare providers. With the rising prevalence of allergic conditions, the demand for antihistamine-based intranasal devices is set to increase, further bolstering market growth.

Decongestants :

Decongestants are widely utilized in intranasal formulations to provide quick relief from nasal congestion caused by allergies or colds. These ingredients work by constricting blood vessels in the nasal passages, leading to reduced swelling and improved airflow. The immediate action of intranasal decongestants makes them a valuable option for patients seeking rapid symptom relief. As the prevalence of respiratory infections and allergies continues to rise, the market for intranasal decongestants is expected to expand significantly, driven by the demand for effective and fast-acting treatments.

Vaccines :

Vaccines represent an innovative ingredient type increasingly found in intranasal drug delivery systems. The ability to administer vaccines intranasally offers a non-invasive solution that can enhance patient compliance, particularly among those who fear needles. This method of delivery is gaining attention, especially in response to the COVID-19 pandemic, prompting research into various intranasal vaccine formulations. As more vaccines receive regulatory approval for intranasal administration, this ingredient type is poised for significant growth, reflecting the market’s responsiveness to emerging public health needs.

Others :

The "Others" category in ingredient types includes various additional compounds that may be used in intranasal drug delivery devices, such as pain relievers, neurotransmitters, or other therapeutic agents that require rapid systemic delivery. Research continues to explore the potential of various ingredients that can be effectively administered intranasally, expanding the scope of treatments available to patients. As innovation in this field progresses, it is anticipated that new ingredient types will emerge, further diversifying the offerings within the intranasal drug delivery device market.

By Region

The North American intranasal drug delivery device market is projected to lead the global landscape, with a market share expected to reach around USD 2.1 billion by 2035. The growth in this region can be attributed to a combination of factors, including a high prevalence of allergies, chronic respiratory diseases, and a strong emphasis on research and development. The presence of key pharmaceutical companies and healthcare infrastructure, coupled with increasing consumer awareness and adoption of advanced medical technologies, positions North America as a dominant region in the intranasal drug delivery sector. With a CAGR of approximately 7.5%, this market segment is expected to witness substantial growth over the forecast period.

In Europe, the intranasal drug delivery device market is estimated to attain a valuation of around USD 1.6 billion by 2035, propelled by the rising incidence of allergic conditions and respiratory disorders. The European market benefits from a well-established healthcare system, which facilitates the adoption of innovative intranasal devices. Additionally, regulatory frameworks governing drug delivery technologies are conducive to the introduction of novel products, thus fostering market growth. As public health campaigns promote awareness about intranasal therapies, the European market is set to experience a consistent growth trajectory, contributing significantly to the global landscape.

Opportunities

The intranasal drug delivery device market presents numerous opportunities for stakeholders, particularly in the realm of product innovation. As technology evolves, the incorporation of smart features into intranasal devices, such as dosage tracking and user feedback systems, offers a pathway to enhance patient engagement and adherence. Additionally, the increasing demand for personalized medicine paves the way for the development of tailored intranasal formulations that address specific patient needs. Manufacturers can also explore collaborations with research institutions to expedite R&D processes, thereby facilitating the introduction of next-generation intranasal devices that promise improved efficacy and user experience. The focus on preventative healthcare and the rising interest in non-invasive treatment modalities are likely to open new avenues for market growth.

Furthermore, the global expansion of e-commerce and online pharmacies provides a unique opportunity for market penetration. As consumers increasingly turn to digital platforms for their healthcare needs, manufacturers can capitalize on this trend by enhancing their online presence and distribution strategies. Developing targeted marketing campaigns that emphasize the benefits of intranasal therapies and leveraging social media for patient education can further boost demand. The growing trend of telemedicine also holds potential for the intranasal drug delivery market, as healthcare providers can recommend intranasal devices during virtual consultations, ensuring patients receive timely treatments tailored to their conditions. Such strategic initiatives can significantly enhance market visibility and drive sales of intranasal drug delivery devices.

Threats

Despite its growth potential, the intranasal drug delivery device market faces several threats that could hinder its progress. One significant challenge is the regulatory landscape, where strict guidelines and approval processes can delay the introduction of new products into the market. Manufacturers must navigate complex regulatory requirements, which can vary by region, potentially impacting time-to-market for innovative devices. Additionally, competition from alternative drug delivery systems, such as oral and injectable formats, poses a threat as healthcare providers and patients may prefer more traditional delivery methods. The market also faces issues concerning product recalls or safety concerns, which can damage brand reputation and consumer trust. Thus, addressing these challenges is crucial for stakeholders aiming to maintain a competitive edge in the evolving market landscape.

Another considerable threat to the intranasal drug delivery device market is the potential for market saturation. As more companies enter the space, the influx of similar products could lead to fierce competition and price wars, ultimately impacting profit margins. Furthermore, the prevalence of counterfeit products in the pharmaceutical industry presents a significant challenge, as these substandard devices can undermine consumer confidence in legitimate products. Stakeholders must focus on ensuring quality and safety standards to combat these threats. Strategic partnerships, continuous innovation, and effective marketing strategies will be necessary to mitigate these challenges and ensure sustained growth within the market.

Competitor Outlook

• Johnson & Johnson
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Sanofi S.A.
• Mylan N.V.
• Merck & Co., Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Roche Holding AG
• Gilead Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Hikma Pharmaceuticals PLC
• Otsuka Pharmaceutical Co., Ltd.
• UCB S.A.

The competitive landscape of the intranasal drug delivery device market is characterized by a mix of established pharmaceutical giants and innovative startups, all vying for market share through product differentiation and strategic partnerships. Major companies like Johnson & Johnson and Pfizer Inc. have leveraged their extensive R&D capabilities to develop cutting-edge intranasal formulations, ensuring they remain at the forefront of the market. These organizations often invest heavily in clinical trials to demonstrate the efficacy and safety of their products, which helps build consumer trust and enhances their brand reputation. Furthermore, collaborations with academic institutions and healthcare providers allow them to stay aligned with clinical needs and emerging trends, facilitating the successful introduction of new devices.

In addition to established players, emerging companies are gaining traction in the intranasal drug delivery space by focusing on niche markets and innovative solutions. For instance, companies specializing in intranasal vaccines have seen increased interest due to the demand for non-invasive vaccination options. These innovators are often agile, allowing them to adapt quickly to changing market dynamics and consumer preferences. This flexibility enables them to capture segments of the market that may be overlooked by larger competitors. As the demand for intranasal drug delivery devices continues to grow, the competitive landscape will likely evolve, requiring established companies to remain vigilant and responsive to new entrants and their novel approaches.

Furthermore, regional players are also emerging, particularly in Asia Pacific and Latin America, where growing healthcare markets present lucrative opportunities for intranasal device manufacturers. These companies focus on local production and distribution, catering to specific regional healthcare needs and preferences. As globalization and digitalization pave the way for increased access to healthcare products, these regional players are well-positioned to disrupt the market by offering tailored solutions that address local challenges. With the rapid advancements in technology and a growing portfolio of intranasal formulations, the competitive dynamics of this market will continue to evolve, presenting both challenges and opportunities for all stakeholders.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hikma Pharmaceuticals PLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Otsuka Pharmaceutical Co., Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Intranasal Drug Delivery Device Sales Market, By Application
    • 6.1.1 Allergy
    • 6.1.2 Pain Management
    • 6.1.3 Vaccination
    • 6.1.4 Hormonal Disorders
    • 6.1.5 Others
  • 6.2 Intranasal Drug Delivery Device Sales Market, By Product Type
    • 6.2.1 Sprays
    • 6.2.2 Drops
    • 6.2.3 Powders
    • 6.2.4 Gels
    • 6.2.5 Others
  • 6.3 Intranasal Drug Delivery Device Sales Market, By Ingredient Type
    • 6.3.1 Corticosteroids
    • 6.3.2 Antihistamines
    • 6.3.3 Decongestants
    • 6.3.4 Vaccines
    • 6.3.5 Others
  • 6.4 Intranasal Drug Delivery Device Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Intranasal Drug Delivery Device Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Intranasal Drug Delivery Device Sales market is categorized based on

By Product Type

• Sprays
• Drops
• Powders
• Gels
• Others

By Application

• Allergy
• Pain Management
• Vaccination
• Hormonal Disorders
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Corticosteroids
• Antihistamines
• Decongestants
• Vaccines
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Sanofi S.A.
• Mylan N.V.
• Merck & Co., Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Roche Holding AG
• Gilead Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Hikma Pharmaceuticals PLC
• Otsuka Pharmaceutical Co., Ltd.
• UCB S.A.